中国肺癌杂志最新文献

{"title":"[Chinese Expert Consensus on Clinical Management of Oncogene Addicted \u2029Non-small Cell Lung Cancer with Leptomeningeal Metastasis (2026 Edition)].","authors":"","doi":"10.3779/j.issn.1009-3419.2025.102.39","DOIUrl":"10.3779/j.issn.1009-3419.2025.102.39","url":null,"abstract":"<p><p>The prognosis for non-small cell lung cancer (NSCLC) with leptomeningeal metastasis (LM) is extremely poor. However, in oncogene addicted patients, the emergence of targeted therapies with high central nervous system (CNS) penetration is significantly reshaping the treatment landscape. Existing guidelines, which often favor conservative strategies, are no longer sufficient to meet the demands of precision medicine. To address this challenge, the Metastasis Lung Cancer Collaboration Group, Youth Specialists Committee of Beijing Medical Reward Foundation convened multidisciplinary experts from Medical Oncology, Radiology, Pathology, Radiotherapy, and Neurosurgery. Based on evidence-based medicine from the past decade and clinical practice experience, they have developed the Chinese expert consensus on clinical management of oncogene addicted NSCLC with leptomeningeal metastasis (2026 edition). This consensus emphasizes that the diagnosis of LM should be based on a comprehensive assessment of clinical symptoms, magnetic resonance imaging (MRI), and cerebrospinal fluid (CSF) cytology. It also highlights the critical role of CSF molecular liquid biopsy in clarifying driver gene status and assessing treatment efficacy. In terms of treatment, this consensus advocates for a fundamental paradigm shift: therapy should be led by a multidisciplinary team (MDT), with high-CNS-penetration targeted therapies as the first-line intervention, while local treatments (such as intrathecal injection and radiotherapy) are positioned as supplementary measures. The consensus provides a series of expert recommendations on key aspects, including the selection of high-CNS-penetration tyrosine kinase inhibitors (TKIs), the application of intrathecal chemotherapy, the timing of radiotherapy, and palliative surgery. It aims to establish proactive, individualized treatment standards for patients with NSCLC LM in China, based on molecular subtyping and MDT collaboration, thereby improving patient survival outcomes.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 1","pages":"1-14"},"PeriodicalIF":0.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046444/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expression, Prognostic and Functional Analysis of SRSF Family Proteins \u2029in Non-small Cell Lung Cancer].","authors":"Shuqi Tu, Yuhao Chen, Yalong Zhang, Qiang Chen, Yaguang Fan, Yixuan Wang, Yang Zhang, Sinuo Li, Jun Chen, Hongli Pan, Xuexia Zhou, Xuebing Li","doi":"10.3779/j.issn.1009-3419.2026.106.02","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.02","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Non-small cell lung cancer (NSCLC) is one of the leading causes of cancer-related deaths worldwide, and its occurrence and development are closely related to complex molecular mechanisms. Alternative splicing of precursor mRNA is a key step in gene expression regulation, and its dysregulation is common in tumors. The serine/arginine-rich splicing factor (SRSF) family, a core protein family in splicing regulation, has been confirmed to play oncogenic roles in various cancers. However, systematic research on the SRSF family in NSCLC remains insufficient. This study aims to systematically analyze the specific expression patterns, clinical prognostic value, collaborative mechanisms and potential biological functions of SRSF individual members in NSCLC by the combination of bioinformatics analysis and experimental verification.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study integrated NSCLC transcriptome data and clinical information from public databases such as The Cancer Genome Atlas (TCGA) and the Cancer Cell Line Encyclopedia (CCLE), and systematically analyzed the differential expressions of SRSF family members. Kaplan-Meier survival analysis was performed to assess the correlation between the expression levels of each SRSF member and patients' overall survival (OS). Furthermore, co-expression network analysis and Gene Ontology (GO)/Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were employed to explore the biological processes and signaling pathways potentially involved by the SRSF family. Moreover, the expression and function of key members were verified by reverse transcription quantitative polymerase chain reaction (RT-qPCR), cell counting kit-8 (CCK-8) and cell proliferation experiments in clinical samples and cell lines.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Multiple members of the SRSF family (e.g., SRSF1, SRSF2, SRSF3, SRSF6, SRSF7, SRSF9, SRSF10) were found to be significantly upregulated in NSCLC tissues and cell lines. Survival analysis indicated that high expression of SRSF9 was associated with poor prognosis, while low expressions of SRSF11 and SRSF12 also indicated unfavorable outcomes. Functional enrichment analysis revealed that the SRSF family is not only involved in RNA splicing but also significantly enriched in pathways related to protein homeostasis, cellular stress response, and neurodegenerative diseases. In vitro experiments confirmed that knockdown of SRSF1, SRSF2, SRSF6, SRSF9 and SRSF10 significantly inhibited the proliferation of NSCLC cells.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;This study systematically delineates the expression and functional landscape of the SRSF family in NSCLC, confirming their potential as prognostic biomarkers and therapeutic targets. The findings suggest that the SRSF family may drive NSCLC progression by disrupting cellular homeostasis, a crucial aspect of tumorigenesis, such as protein homeostasis and stress responses. This research provides a","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 1","pages":"15-25"},"PeriodicalIF":0.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research Progress on Glycolytic Reprogramming and Lactylation Crosstalk in Tumors].","authors":"Yilin Feng, Ying Sun, Xu Hao, Huitong Yang, Anqi Lu, Yuan Liu, Jinchan Xia, Long Feng, Min Jiang, Xiru Zhao","doi":"10.3779/j.issn.1009-3419.2026.101.02","DOIUrl":"10.3779/j.issn.1009-3419.2026.101.02","url":null,"abstract":"<p><p>Metabolic reprogramming is a hallmark of cancer, with the Warburg effect-driven aerobic glycolysis leading to a substantial accumulation of lactate in the tumor microenvironment. For a long time, lactate was considered a mere metabolic end product; however, recent studies have found that it acts as an important signaling molecule, profoundly influencing tumor progression by inducing a novel post-translational modification - lactylation. Lactylation, driven by lactate, occurs on both histones and non-histone proteins and is finely regulated by the 'writer' 'eraser' and 'reader' mechanisms, thereby altering the function of target proteins and gene expression. This review systematically explores the bidirectional regulatory network between glycolytic reprogramming and lactylation: on one hand, key glycolytic regulators promote lactate production, thereby increasing lactylation levels; on the other hand, lactylation can feedback to regulate the activity and expression of key glycolytic enzymes, forming a pro-tumor positive feedback loop. This interaction plays a central role in tumor proliferation, metastasis, DNA damage repair, and immune evasion. Consequently, targeting lactate production, lactate transport, or the lactylation process itself has emerged as a highly promising anti-cancer strategy and shows potential synergy with existing therapies such as immune checkpoint inhibitors. In-depth analysis of the glycolysis-lactylation axis will provide a crucial theoretical basis for developing novel cancer treatment approaches.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 1","pages":"59-67"},"PeriodicalIF":0.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Role of Receptor Tyrosine Kinase AXL in Cancer Targeted Therapy Drug Resistance].","authors":"Sutong Zhan, Peilin Chen, Tangfeng Lv, Yong Song","doi":"10.3779/j.issn.1009-3419.2026.101.01","DOIUrl":"10.3779/j.issn.1009-3419.2026.101.01","url":null,"abstract":"<p><p>Although targeted therapy has made significant advances in cancer treatment throughout these years, drug resistance still remains a major obstacle. Plenty of evidence has proved that abnormal expression of receptor tyrosine kinase AXL is associated with targeted therapy resistance and poor clinical outcomes. AXL drives drug resistance through diverse mechanisms, including altering tumor cell phenotypes, orchestrating DNA damage response process, promoting the activation of bypass signals, or interacting with other receptor tyrosine kinases. Preclinical and clinical studies have demonstrated that combined inhibition of AXL and the other target can enhance the efficacy of various targeted therapies and improve outcomes for patients with drug resistance. This review summarizes recent advances in the specific roles of AXL in targeted therapy resistance and AXL-targeted treatment strategies. It further explores the potential clinical value of combinatorial approaches involving AXL inhibition and discusses future directions for its application in developing novel targeted therapies and advancing precision oncology treatment. \u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 1","pages":"68-76"},"PeriodicalIF":0.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Application of the International System for Serous Fluid Cytopathology \u2029in the Stratified Diagnosis of Lung Cancer-associated Serous Effusions].","authors":"Wei Wu, Jian Zhang, Cong Wang, Xinxiang Chang, Yue Sun, Linlin Zhao, Shize Wang, Yiyun Zhang, Huan Zhao, Huiqin Guo, Zhihui Zhang","doi":"10.3779/j.issn.1009-3419.2026.102.03","DOIUrl":"10.3779/j.issn.1009-3419.2026.102.03","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Serous effusion is a common complication in patients with advanced lung cancer, which often indicates that the tumor has metastasized to the pleura or other serosal membranes. It is essential to achieve an accurate diagnosis and pathological classification of tumor cells in effusion to guide clinical treatment. However, there are limitations to relying solely on morphological diagnosis, especially in atypical cases where diagnostic uncertainty is common. The International System for Serous Fluid Cytopathology (TIS) proposes a standardized hierarchical diagnostic framework that integrates morphology and auxiliary techniques. Nevertheless, its clinical application value in the Chinese lung cancer population remains insufficiently validated. This study aimed to systematically evaluate the diagnostic performance of the TIS system in the assessment and classification of serous effusions based on a large sample of lung cancer cases.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective analysis was conducted on 1274 serous effusion specimens from the Cancer Hospital Chinese Academy of Medical Sciences between January 2018 and December 2023, all of which were derived from patients with lung cancer confirmed by histopathology and/or clinical history. The diagnostic procedure strictly followed the TIS protocol, which commenced with the morphological evaluation and assignment to categories I-V. For some cases with ambiguous morphology (categories III and IV) and category V, immunocytochemistry (ICC) was performed using cell blocks to comprehensively determine the final diagnostic category, tumor subtyping, and tumor origin. Statistical analyses were applied to assess the diagnostic concordance between initial morphology and combined ICC. Additionally, the trend in category changes and the clinical value of ICC in pathological subtyping and origin determination were analyzed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Based on morphology alone, 83.1% (1059/1274) of cases were classified as malignant (category V), while 12.3% (157/1274) were categorized as indeterminate (categories III or IV). Further analysis of the 69 cases that underwent ICC detection revealed that the rate of upgraded diagnosis was 85.5% (59/69), and the upgrading proportion in category IV cases (89.6%, 43/48) was significantly higher than that in category III cases (76.2%, 16/21). Furthermore, 7.2% (5/69) of category III cases were downgraded to benign (category II), while another 7.2% (5/69) remained unchanged due to insufficient cellularity or poor differentiation. These findings indicate that ICC can markedly improve the diagnostic accuracy for indeterminate serous effusions in lung cancer. Among definitively malignant cases, ICC was employed to enable subtyping and origin assessment in 542 cases, achieving precise pathological classification in 533 cases (98.3%): including adenocarcinoma (86.7%), small cell carcinoma (4.4%), and squamous cell carcinoma (3.9%), and con","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 1","pages":"26-34"},"PeriodicalIF":0.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595129","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Appropriate Duration of First-line Immunotherapy for \u2029Advanced NSCLC and Predictive Factors].","authors":"Yue Yin, Xiaotong Guo, Jing Ai, Jibo Yue, Lili Deng","doi":"10.3779/j.issn.1009-3419.2026.106.01","DOIUrl":"10.3779/j.issn.1009-3419.2026.106.01","url":null,"abstract":"<p><p>First-line immunotherapy for advanced non-small cell lung cancer (NSCLC) shows significant survival benefits in patients without driver mutations, but the optimal duration of treatment remains controversial. Some studies support limiting immunotherapy to 2 years, arguing that longer treatment does not bring additional survival benefits; while other studies believe that treatment should continue until disease progression to maximize survival benefits. This article systematically reviews the current research progress on the duration of immunotherapy and discusses the potential predictive value of biomarkers such as circulating tumor DNA (ctDNA), the best efficacy response, and programmed cell death ligand 1 (PD-L1) expression levels in individualized treatment decisions. More prospective studies, especially biomarker-driven trials, are still needed to clarify the optimal duration of treatment and establish an individualized treatment strategy based on multidimensional indicators.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 1","pages":"35-46"},"PeriodicalIF":0.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Significance of Extranodal Extension in Non-small Cell Lung Cancer: \u2029Current Status and Future Prospects].","authors":"Han Liang, Yajie Meng, Qi Wang, Caifan Li, Hao Yang, Xudong Xiang","doi":"10.3779/j.issn.1009-3419.2026.101.03","DOIUrl":"10.3779/j.issn.1009-3419.2026.101.03","url":null,"abstract":"<p><p>Global cancer statistics in 2022 ranked lung cancer as the leading cause of cancer incidence and mortality worldwide, with lymph node metastasis serving as a pivotal determinant of prognosis and treatment strategy. Extranodal extension (ENE) refers to the pathological phenomenon where tumor cells breach the lymph node capsule and invade surrounding tissues. In non-small cell lung cancer (NSCLC), although ENE has not yet been formally incorporated into the tumor-node-metastasis (TNM) staging system, its clinical value is gaining increasing attention. This review systematically summarizes the current research progress regarding the definition, diagnostic approaches, prognostic significance, and treatment implications of ENE in NSCLC, analyzes existing challenges, and proposes future directions. The goal of this paper is to provide insights for optimizing clinical practice and guiding subsequent research.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"29 1","pages":"47-58"},"PeriodicalIF":0.0,"publicationDate":"2026-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13046438/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147595167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Characteristics and Prognosis Analysis of Thoracic SMARCA4-deficient\u2029Undifferentiated Tumor versus SMARCA4-deficient Non-small Cell Lung Cancer].","authors":"Yingxue Guo, Jinlan Yang, Xiang Lv, Xijun Liu, Fengxiang Li, Jinzhi Wang, Peng Zhang, Jianbin Li, Wei Wang","doi":"10.3779/j.issn.1009-3419.2025.102.45","DOIUrl":"10.3779/j.issn.1009-3419.2025.102.45","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a newly defined type of epithelial tumor in the 2021 World Health Organization (WHO) fifth edition classification of thoracic tumors, with a low incidence. Currently, its treatment and prognosis remain unclear. Pathologically, it can be distinguished from SMARCA4-deficient non-small cell lung cancer (SMARCA4-dNSCLC) based on histological morphology and immunohistochemistry, yet whether there are differences in their clinical features, sensitivity to radiotherapy, and prognosis remains unknown. This study aimed to analyze the clinical characteristics of patients with SMARCA4-UT and SMARCA4-dNSCLC and to identify prognostic factors.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective analysis was performed on pathologically confirmed SMARCA4-UT and SMARCA4-dNSCLC patients with complete follow-up data who were admitted to Shandong First Medical University Affiliated Tumor Hospital from June 2022 to February 2025. The differences in clinicopathological characteristics and imaging findings between the two groups were statistically analyzed, and the impacts of surgery, radiotherapy, immunotherapy, and clinicopathological factors on the prognosis of patients in both groups were assessed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 27 SMARCA4-UT patients and 40 SMARCA4-dNSCLC patients were enrolled. Both groups showed similar biological characteristics in terms of gender, age, smoking history, tumor size, symptoms, stage, presence of pleural metastasis, neutrophil-to-lymphocyte ratio (NLR), and systemic immune-inflammation index (SII). However, there were differences in the predilection sites: SMARCA4-UT occurred more frequently in the mediastinal pleura (22.22%) and right lower lobe (25.93%), while SMARCA4-dNSCLC occurred more frequently in the right upper lobe (25.00%) and left upper lobe (22.50%) (P&lt;0.05). Furthermore, SMARCA4-UT more often presented with local invasion into adjacent structures and more extensive lymph node metastasis (proportion with metastasis in ≥5 lymph node stations: 55.56% vs 27.50%). Both types showed high sensitivity to radiotherapy, with a 6-month local control rate (LCR) of 84.62% vs 83.33% after radiotherapy; the objective response rate (ORR) of immunotherapy was 91.67% vs 68.18% (P&gt;0.05). Regarding survival, the two groups did not show significant differences in progression-free survival (PFS) or overall survival (OS). Cox multivariate regression analysis indicated that surgery could improve the prognosis of both types, while a high NLR (≥3.57) was a predictor of poor prognosis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;SMARCA4-UT and SMARCA4-dNSCLC share similar clinical characteristics and survival outcomes, with minor differences in local invasion, mediastinal lymph node metastasis, and primary tumor location. Surgery improved survival in both groups. Although both tumor types exhibited high sensitivity to radiotherapy, this did not t","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 12","pages":"896-904"},"PeriodicalIF":0.0,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972582/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147349436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[p53-SOAT1 Axis: A Novel Target for Tumor Lipid Metabolism and Therapy].","authors":"Xi Yu, Yuting Xiao, Bowen Xu, Xinhui Li, Hongmei Wang, Dunqiang Ren","doi":"10.3779/j.issn.1009-3419.2025.106.34","DOIUrl":"10.3779/j.issn.1009-3419.2025.106.34","url":null,"abstract":"<p><p>Cancer treatment is a significant challenge facing global medicine, with complex molecular mechanisms and drug resistance being key factors limiting treatment outcomes. Abnormal lipid metabolism is one of the important characteristics of tumors, providing metabolic support for the growth, proliferation, migration, and invasion of tumor cells. Tumor suppressor p53 protein and sterol O-acyltransferase 1 (SOAT1) play an important role in regulating cellular lipid metabolism and are closely related to the occurrence, development, and prognosis of various tumors. p53 protein regulates tumor lipid metabolism through multiple signaling pathways, while SOAT1, as a key enzyme in cholesterol esterification, is highly expressed in many tumors and accelerates tumor progression. Recent studies have shown that there may be a functional association between p53 protein and SOAT1, coordinating the regulation of lipid homeostasis in tumor cells. This article reviews the research progress on p53 protein and SOAT1 in tumor lipid metabolism, focusing on the potential mechanisms of action of the p53-SOAT1 axis in tumor development, and prospects its application prospects as a target for cancer treatment.\u2029.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 12","pages":"924-930"},"PeriodicalIF":0.0,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147349600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy and Safety of High-dose Furmonertinib plus Intrathecal Pemetrexed \u2029for EGFR-mutant Non-small Cell Lung Cancer with Leptomeningeal Metastasis].","authors":"Xin Chen, Mingyang He, Cen Chen, Cheng Jiang, Huiying Li, Yongjuan Lin, Tingting Yu, Yu Xie, Aibin Guo, Mingmin Huang, Zhenyu Yin, Tianli Zhang","doi":"10.3779/j.issn.1009-3419.2025.101.24","DOIUrl":"10.3779/j.issn.1009-3419.2025.101.24","url":null,"abstract":"<p><strong>Background: </strong>Leptomeningeal metastasis (LM) is a devastating complication of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC), with a poor prognosis. While high-dose third-generation EGFR-tyrosine kinase inhibitors (EGFR-TKIs) can enhance drug concentrations in the central nervous system, their efficacy as monotherapy remains limited. Intrathecal Pemetrexed (IP) offers a promising local treatment approach by bypassing the blood-brain barrier and acting directly within the cerebrospinal fluid. However, clinical data on the efficacy and safety of combining high-dose third-generation EGFR-TKIs Furmonertinib (160 mg/d) with IP in EGFR-mutant NSCLC-LM patients are still scarce. Therefore, this study aims to evaluate the efficacy and safety of this combination regimen in this population to provide real-world data support for clinical practice.</p><p><strong>Methods: </strong>In this retrospective study, 40 patients with EGFR-mutant NSCLC-LM were enrolled at Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University between June 2021 and December 2024. All patients received oral Furmonertinib (160 mg/d) combined with IP. Primary endpoints were intracranial progression-free survival (iPFS), overall survival (OS), overall response rate (ORR) and adverse events. Survival analysis was performed using the Kaplan-Meier method, and prognostic factors were assessed via Cox proportional hazards regression by collecting the clinical data and follow-up information of the patients.</p><p><strong>Results: </strong>After a median follow-up of 20.0 months, the combination therapy demonstrated significant efficacy. The ORR was 85.0%, with a median iPFS of 9.6 months and a median OS of 12.6 months. The 6-, 12- and 24-month OS rates were 79.9%, 53.9% and 27.0%, respectively. Multivariate analysis identified combination therapy with Bevacizumab as an independent protective factor [hazard ratio (HR)=0.283, 95%CI: 0.114-0.702, P=0.006], while a poor baseline Karnofsky performance status (KPS) score was an independent risk factor (HR=3.069, 95%CI: 1.313-7.170, P=0.010). Adverse events were primarily grade 1-2, including myelosuppression (42.5%), elevated transaminases (22.5%), and gastrointestinal reactions (nausea and/or vomiting, 20.0%). Only one case of grade 4 myelosuppression was reported and resolved after supportive care.</p><p><strong>Conclusions: </strong>High-dose Furmonertinib combined with IP is an effective and well-tolerated regimen for EGFR-mutant NSCLC-LM. The addition of Bevacizumab may further improve outcomes, offering a promising strategy for refractory patients.</p>","PeriodicalId":39317,"journal":{"name":"中国肺癌杂志","volume":"28 12","pages":"905-915"},"PeriodicalIF":0.0,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12972578/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147349424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}